This can lead to dosing mistakes, Jaworski said
The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)
Also approved for weight loss in obese people with diabetes and overweight pediatric patients aged twelve and over
Ozempic is also approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, in adults with type 2 diabetes and known cardiovascular disease
This ensures your safety and optimizes your results